Timeline of regulatory (US Food and Drug Administration) approvals for currently used disease-modifying antirheumatic drugs over the past 10 years. Major regulatory trials used in approval of each agent are listed below the agent. For reference, methotrexate was approved in 1985, cyclosporine in 1995. ABA, abatacept; ADA, adalimumab; AIM, Abatacept in Inadequate Responders to Methotrexate; ASSURE, Abatacept Study of Safety in Use with Other Rheumatoid Arthritis Therapies; ATTAIN, Abatacept Trial in Treatment of Anti-Tumor Necrosis Factor Inadequate Responders; ATTRACT, Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy; DANCER, Dose-Ranging Assessment International Clinical Evaluation of Rituximab in Rheumatoid Arthritis; ETN, etanercept; INF, infliximab; LEF, leflunomide; MTX, methotrexate; REFLEX, Randomized Evaluation of Long-Term Efficacy of Rituximab; RTX, rituximab; STAR, Safety Trial of Adalimumab in Rheumatoid Arthritis.
Strand and Sokolove Arthritis Research & Therapy 2009 11:205 doi:10.1186/ar2555